科济药业-B 港股通 空最新回购 (2025-12-29) 官网 ( 02171.hk) | -90.30 | 11.28 | 0% | 上市时间2021-06-18股价16.32港币涨跌幅-1.69%成交金额9,283.93万港币换手率0.92%市值98.33亿港币H股市值98.33亿港币总股本6.02亿H股本6.02亿每手股数500上市至今年化投资收益率-11.54%港股通持仓占H股比例27.17% (26.29亿港币2026-06-03) 累计做空占H股比例4.61% (5.04亿港币2026-05-29) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 97.58 | 市净率 | 3.79 | 股息率 | 0.44% | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 备注 (4): | 双击编辑备注 |
科济药业-B(02171) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 趙向可 | Independent Non Executive Director - A/F | 2023-07-04 | -- | |
| 2 | 李華兵 | Independent Non Executive Director | 2023-03-09 | -- | |
| 3 | 蔣華 | Executive Director | 2022-08-01 | -- | |
| 4 | 顏光美 | Independent Non Executive Director | 2021-06-18 | -- | |
| 5 | 蘇德揚 | Independent Non Executive Director - A/F | 2021-06-18 | 2023-06-30 | |
| 6 | 樊春海 | Independent Non Executive Director | 2021-06-18 | 2023-01-11 | |
| 7 | 郭華清 | Non Executive Director | 2020-09-18 | -- | |
| 8 | 謝榕剛 | Non Executive Director | 2020-09-18 | -- | |
| 9 | 郭炳森 | Non Executive Director | 2018-09-13 | -- | |
| 10 | 王華茂 | Executive Director | 2018-09-13 | -- | |
| 11 | 趙雅超 | Non Executive Director | 2018-09-13 | 2022-05-27 | |
| 12 | 李宗海 | Executive Director | 2018-02-09 | -- |